Univercells strengthens Board with Appointment of Timothy E. Morris
Univercells S.A. (“Univercells”) management and Board of Directors, reached an agreement today with Timothy E. Morris to present him for official appointment as an independent director to its Board of Directors at the next annual general assembly on 8 February 2022. Mr. Morris brings over 38 years of professional finance and accounting experience and 25 years as a Chief Financial Officer for publicly traded biopharmaceutical companies. Following the appointment of Mr. Morris, the Board will be comprised of 8 directors, 6 of whom are independent.
“We are pleased to welcome a top-level executive, such as Tim, to the Board”, said Doug Neugold, Chairman of the Board of Univercells. “Tim’s extensive professional and accounting experience will drive Univercells to the next level of maturity, as we transition to being a publicly traded company.”
Mr. Morris, 60, has been the COO and CFO of Humanigen, Inc. (HGEN) since 2020, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Prior to joining in an operating role, he served as Board member and Audit Committee Chair for four years.
Mr. Morris will chair the Audit Committee of Univercells. He brings extensive financial and commercial experience in the biotech sector. Prior to Humanigen, Mr. Morris held the positions of CFO at Iovance Biotherapeutics (IOVA), AcelRx (ACRX), VIVUS, Inc (VVUS) and Questcor Pharmaceuticals (QCOR). During his career as CFO, he raised over $2.0 billion in equity and convertible securities for 7 different companies, including IPOs. He also developed extensive deal experience, having completed over 90 transactions with a combined value in excess of $5.0 billion.
“Univercells has built a group of companies focused on making biologics available to all. I am honored and humbled to join this world class board of directors, investors and executive team to help fulfill this mission”, commented Timothy Morris. “Sustainability is at the core of the company and the employees, and I am elated to assist with their efforts as they look to expand in to the United States and seek a listing on a US stock exchange.”
In addition to Univercells, Mr. Morris serves on the Board of Directors of Humanetics Corporation, a private company and DBV Technologies (Euronext: DBV- ISIN: FR0010417345 Nasdaq: DBVT). He previously served as a non-executive director of PAION, Inc, the US subsidiary of PAION AG.